Administration of Methylprednisolone for Prevention of Ovarian Hyper Stimulation Syndrome

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1/PHASE2

Total Enrollment

218 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-10-31

Study Completion Date

2010-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is a prospective randomized clinical controlled trial to assess the efficacy of the Methylprednisolone for preventing ovarian hyper stimulation syndrome in in vitro fertilization (IVF) cycles.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Methylprednisolone Addition in IVF Treatment of Infertile Couples

NCT01220791

In Vitro Fertilization

UNKNOWN PHASE4

Evaluation of Different Luteal Phase Support Methods in Patients With Poor Ovarian Response

NCT02798653

Infertility

UNKNOWN PHASE3

Efficacy and Safety of Medication Used to Stimulate Ovulation

NCT02715336

IVF Cycle Ovarian Stimulation Egg Retrieval +3 more

UNKNOWN PHASE4

Inositols and FSH in IVF

NCT04576546

Amount of FSH Units During Ovarian Stimulation Protocols

COMPLETED NA

Human Growth Hormone Pre-treatment for 6 Weeks Prior to Ovulation Induction for IVF

NCT02179255

Female Infertility Due to Diminished Ovarian Reserve

UNKNOWN PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Ovarian hyper stimulation syndrome is the most serious complication of ovarian stimulation which might be life threatening in the severe forms. Since there is still no definite cure for this syndrome, prevention is considered as an essential and vital issue. The objective of this study is to determine the effect of Methylprednisolone to prevent ovarian hyper stimulation syndrome in IVF cycles.

The study population comprises all infertile patients with diagnosis of polycystic ovarian syndrome which will undergo of in-vitro fertilization. The PCO subjects will be recognized based on the Rotterdam criteria inclusive the presence of least 2 signs of oligomenorrhea, hyper androgynism (clinical or laboratory), LH/FSH\>2 and ovarian morphological evidences in Doppler ultrasound.

The existence of more than 20 follicles in both ovaries and E2 concentration \>4000 pg/ml will be considered as the OHSS risk factors.

In this study all eligible patients will be randomly allocated into two study groups by a computerized randomization method:

Treatment group (case) will be administered 16 mg Methylprednisolone initiated from the first day of stimulation and will be tapered after the first pregnancy test (day 13 after the embryo transfer). Furthermore, these patients will receive a bolus IV dose methylprednisolone, 1g on the day of egg collection and embryo transfer.

Patients in the control group will not receive any treatment with glucocorticoids. If each group confronts with every kind of high risk signs or symptoms, they will undergo coasting or gonadotropin withdrawal or other treatment strategies.

The presence of OHSS is defined in accordance with the Golan 5 grade system and women who at least are at grade 2 of this classification (Mild) considered as OHSS cases and will experience abdominal distention and discomfort, nausea and vomiting and/or diarrhea and enlargement of ovaries(5-12cm). In Moderate forms, ultrasound evidences of ascites will be observed and severe OHSS accompany with clinical signs of ascites, hydrothorax, breathing disorders, hemoconcentration, coagulopathy and renal perfusion decrease.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Ovarian Hyperstimulation Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Case

Administration of Methylprednisolone

Group Type EXPERIMENTAL

Methylprednisolone

Intervention Type DRUG

Administration of Methylprednisolone

Control

Group Type SHAM_COMPARATOR

Control

Intervention Type DRUG

Normal salin injection

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Methylprednisolone

Administration of Methylprednisolone

Intervention Type DRUG

Control

Normal salin injection

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Case

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Poly Cystic Ovarian Syndrome patients
* Indication for IVF/ICSI and Long Protocol ovarian stimulation
* Basal FSH≥10
* Normal BMI (20-25)
* physical health

Exclusion Criteria

* Allergy to GnRH analogues, FSH and corticosteroids
* presence of heart failure, recent myocardial infarction
* Hypertension
* Diabetes mellitus
* epilepsy
* glaucoma
* hypothyroidism
* hepatic failure
* osteoporosis
* peptic ulceration
* renal impairment
* Using drugs that have interaction with corticosteroids such

Minimum Eligible Age

18 Years

Maximum Eligible Age

35 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No